XCUR
Exicure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.29
+4.88%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
Market Cap
$8.44M
MomentumView details →
1D Return
+4.88%
YTD Return
−77.31%
RSI (14)
39.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
Market Cap
$8.44M
RSI (14)
39.4
MomentumView details →
1D Return
+4.88%
YTD Return
−77.31%
SummaryUpdated Jun 1, 2026
Exicure, Inc. (NASDAQ:XCUR) is a biotechnology company founded in 2011 and headquartered in Chicago, Illinois. The company went public in May 2018 and focuses on developing innovative therapies for neurological disorders and hair loss using its proprietary spherical nucleic acid (SNA) technology platform. Exicure operates as a clinical-stage biopharmaceutical company with strategic partnerships including collaborations with major pharmaceutical companies AbbVie and Ipsen to advance its novel therapeutic candidates.
Similar companies
Latest newsMore news →
Exicure announced it will issue 172,058 shares of common stock to GPCR Therapeutics in August 2026 to settle a $1.0 million clinical milestone payment obligation under their License and Collaboration Agreement.32d agoExicure, Inc. announced changes to its Board of Directors and Board committees following actions approved at a special meeting on June 24, 2026.66d agoExicure received a Nasdaq notice for non-compliance with minimum stockholders' equity requirement.86d ago